{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:41:34Z","timestamp":1793522494437,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T00:00:00Z","timestamp":1577059200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T00:00:00Z","timestamp":1577059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006955","name":"U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["NIH R37 AI091476"],"award-info":[{"award-number":["NIH R37 AI091476"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006955","name":"U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["NIH R01 AI1129868"],"award-info":[{"award-number":["NIH R01 AI1129868"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006955","name":"U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["NIH DP1 DA043912"],"award-info":[{"award-number":["NIH DP1 DA043912"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1038\/s41587-019-0357-y","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T12:02:53Z","timestamp":1577102573000},"page":"169-175","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["A reversible RNA on-switch that controls gene expression of AAV-delivered therapeutics in vivo"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7609-9575","authenticated-orcid":false,"given":"Guocai","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary J.","family":"Tickner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai H.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5119-2239","authenticated-orcid":false,"given":"Tianling","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huitian","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2990-5319","authenticated-orcid":false,"given":"Michael","family":"Farzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,23]]},"reference":[{"key":"357_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1146\/annurev-bioeng-071516-044649","volume":"19","author":"JB Black","year":"2017","unstructured":"Black, J. B., Perez-Pinera, P. & Gersbach, C. A. Mammalian synthetic biology: engineering biological systems. Annu. Rev. Biomed. Eng. 19, 249\u2013277 (2017).","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"357_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00005-007-0025-7","volume":"55","author":"HK Alexander","year":"2007","unstructured":"Alexander, H. K. et al. Selected technologies to control genes and their products for experimental and clinical purposes. Arch. Immunol. Ther. Exp. 55, 139\u2013149 (2007).","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"357_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1126\/science.283.5398.88","volume":"283","author":"X Ye","year":"1999","unstructured":"Ye, X. et al. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 283, 88\u201391 (1999).","journal-title":"Science"},{"key":"357_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/gt.2016.13","volume":"23","author":"BE Hjelm","year":"2016","unstructured":"Hjelm, B. E. et al. Mifepristone-inducible transgene expression in neural progenitor cells in vitro and in vivo. Gene Ther. 23, 424\u2013437 (2016).","journal-title":"Gene Ther."},{"key":"357_CR5","doi-asserted-by":"publisher","first-page":"11605","DOI":"10.1128\/JVI.76.22.11605-11611.2002","volume":"76","author":"D Favre","year":"2002","unstructured":"Favre, D. et al. Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J. Virol. 76, 11605\u201311611 (2002).","journal-title":"J. Virol."},{"key":"357_CR6","first-page":"195","volume":"2","author":"A Hayat","year":"2008","unstructured":"Hayat, A., Haria, D. & Salifu, M. O. Erythropoietin stimulating agents in the management of anemia of chronic kidney disease. Patient Prefer. Adherence 2, 195\u2013200 (2008).","journal-title":"Patient Prefer. Adherence"},{"key":"357_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.copbio.2017.03.011","volume":"48","author":"S Auslander","year":"2017","unstructured":"Auslander, S. & Fussenegger, M. Synthetic RNA-based switches for mammalian gene expression control. Curr. Opin. Biotechnol. 48, 54\u201360 (2017).","journal-title":"Curr. Opin. Biotechnol."},{"key":"357_CR8","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S1074-5521(97)90197-6","volume":"4","author":"J Tang","year":"1997","unstructured":"Tang, J. & Breaker, R. R. Rational design of allosteric ribozymes. Chem. Biol. 4, 453\u2013459 (1997).","journal-title":"Chem. Biol."},{"key":"357_CR9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature02844","volume":"431","author":"L Yen","year":"2004","unstructured":"Yen, L. et al. Exogenous control of mammalian gene expression through modulation of RNA self-cleavage. Nature 431, 471\u2013476 (2004).","journal-title":"Nature"},{"key":"357_CR10","doi-asserted-by":"publisher","first-page":"14283","DOI":"10.1073\/pnas.0703961104","volume":"104","author":"MN Win","year":"2007","unstructured":"Win, M. N. & Smolke, C. D. A modular and extensible RNA-based gene-regulatory platform for engineering cellular function. Proc. Natl Acad. Sci. USA 104, 14283\u201314288 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"357_CR11","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.1093\/nar\/gks734","volume":"40","author":"P Ketzer","year":"2012","unstructured":"Ketzer, P., Haas, S. F., Engelhardt, S., Hartig, J. S. & Nettelbeck, D. M. Synthetic riboswitches for external regulation of genes transferred by replication-deficient and oncolytic adenoviruses. Nucleic Acids Res. 40, e167 (2012).","journal-title":"Nucleic Acids Res."},{"key":"357_CR12","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1021\/sb500270h","volume":"4","author":"K Beilstein","year":"2015","unstructured":"Beilstein, K., Wittmann, A., Grez, M. & Suess, B. Conditional control of mammalian gene expression by tetracycline-dependent hammerhead ribozymes. ACS Synth. Biol. 4, 526\u2013534 (2015).","journal-title":"ACS Synth. Biol."},{"key":"357_CR13","doi-asserted-by":"publisher","first-page":"e18858","DOI":"10.7554\/eLife.18858","volume":"5","author":"G Zhong","year":"2016","unstructured":"Zhong, G., Wang, H., Bailey, C. C., Gao, G. & Farzan, M. Rational design of aptazyme riboswitches for efficient control of gene expression in mammalian cells. eLife 5, e18858 (2016).","journal-title":"eLife"},{"key":"357_CR14","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.ymthe.2018.02.021","volume":"26","author":"H Mou","year":"2018","unstructured":"Mou, H. et al. Conditional regulation of gene expression by ligand-induced occlusion of a microRNA target sequence. Mol. Ther. 26, 1277\u20131286 (2018).","journal-title":"Mol. Ther."},{"key":"357_CR15","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nbt.3301","volume":"33","author":"L Wroblewska","year":"2015","unstructured":"Wroblewska, L. et al. Mammalian synthetic circuits with RNA binding proteins for RNA-only delivery. Nat. Biotechnol. 33, 839\u2013841 (2015).","journal-title":"Nat. Biotechnol."},{"key":"357_CR16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang, D., Tai, P. W. L. & Gao, G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 18, 358\u2013378 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"357_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-12-381286-5.00001-9","volume":"120","author":"WG Scott","year":"2013","unstructured":"Scott, W. G., Horan, L. H. & Martick, M. The hammerhead ribozyme: structure, catalysis, and gene regulation. Prog. Mol. Biol. Transl. Sci. 120, 1\u201323 (2013).","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"357_CR18","doi-asserted-by":"publisher","first-page":"W471","DOI":"10.1093\/nar\/gkt290","volume":"41","author":"S Bellaousov","year":"2013","unstructured":"Bellaousov, S., Reuter, J. S., Seetin, M. G. & Mathews, D. H. RNAstructure: web servers for RNA secondary structure prediction and analysis. Nucleic Acids Res. 41, W471\u2013W474 (2013).","journal-title":"Nucleic Acids Res."},{"key":"357_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.cell.2006.06.036","volume":"126","author":"M Martick","year":"2006","unstructured":"Martick, M. & Scott, W. G. Tertiary contacts distant from the active site prime a ribozyme for catalysis. Cell 126, 309\u2013320 (2006).","journal-title":"Cell"},{"key":"357_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.bpj.2017.06.011","volume":"113","author":"S Bottaro","year":"2017","unstructured":"Bottaro, S. & Lindorff-Larsen, K. Mapping the universe of RNA tetraloop folds. Biophysical J. 113, 257\u2013267 (2017).","journal-title":"Biophysical J."},{"key":"357_CR21","doi-asserted-by":"publisher","first-page":"e234","DOI":"10.1371\/journal.pbio.0060234","volume":"6","author":"YI Chi","year":"2008","unstructured":"Chi, Y. I. et al. Capturing hammerhead ribozyme structures in action by modulating general base catalysis. PLoS Biol. 6, e234 (2008).","journal-title":"PLoS Biol."},{"key":"357_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2174\/156802607780487740","volume":"7","author":"JE Summerton","year":"2007","unstructured":"Summerton, J. E. Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity. Curr. Top. Med Chem. 7, 651\u2013660 (2007).","journal-title":"Curr. Top. Med Chem."},{"key":"357_CR23","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","volume":"25","author":"CA Stein","year":"2017","unstructured":"Stein, C. A. & Castanotto, D. FDA-approved oligonucleotide therapies in 2017. Mol. Ther. 25, 1069\u20131075 (2017).","journal-title":"Mol. Ther."},{"key":"357_CR24","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2144\/000113005","volume":"45","author":"PA Morcos","year":"2008","unstructured":"Morcos, P. A., Li, Y. & Jiang, S. Vivo-morpholinos: a non-peptide transporter delivers morpholinos into a wide array of mouse tissues. Biotechniques 45, 613\u2013614, 616, 618 (2008).","journal-title":"Biotechniques"},{"key":"357_CR25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0167-4781(99)00150-5","volume":"1489","author":"J Summerton","year":"1999","unstructured":"Summerton, J. Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim. Biophys. Acta. 1489, 141\u2013158 (1999).","journal-title":"Biochim. Biophys. Acta."},{"key":"357_CR26","doi-asserted-by":"publisher","first-page":"8657","DOI":"10.1073\/pnas.96.15.8657","volume":"96","author":"VM Rivera","year":"1999","unstructured":"Rivera, V. M. et al. Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc. Natl Acad. Sci. USA 96, 8657\u20138662 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"357_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nature10660","volume":"481","author":"AB Balazs","year":"2012","unstructured":"Balazs, A. B. et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481, 81\u201384 (2012).","journal-title":"Nature"},{"key":"357_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nature14264","volume":"519","author":"MR Gardner","year":"2015","unstructured":"Gardner, M. R. et al. AAV-expressed eCD4\u2013Ig provides durable protection from multiple SHIV challenges. Nature 519, 87\u201391 (2015).","journal-title":"Nature"},{"key":"357_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.omtn.2016.12.003","volume":"6","author":"Y Huang","year":"2017","unstructured":"Huang, Y. Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics. Mol. Ther. Nucleic Acids 6, 116\u2013132 (2017).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"357_CR30","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJM199808273390910","volume":"339","author":"JW Adamson","year":"1998","unstructured":"Adamson, J. W. & Eschbach, J. W. Erythropoietin for end-stage renal disease. N. Engl. J. Med. 339, 625\u2013627 (1998).","journal-title":"N. Engl. J. Med."},{"key":"357_CR31","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.bbrc.2005.11.034","volume":"339","author":"DE Lee","year":"2006","unstructured":"Lee, D. E., Son, W., Ha, B. J., Oh, M. S. & Yoo, O. J. The prolonged half-lives of new erythropoietin derivatives via peptide addition. Biochem. Biophys. Res. Commun. 339, 380\u2013385 (2006).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"357_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1053\/j.ajkd.2012.07.014","volume":"61","author":"I Koulouridis","year":"2013","unstructured":"Koulouridis, I., Alfayez, M., Trikalinos, T. A., Balk, E. M. & Jaber, B. L. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am. J. Kidney Dis. 61, 44\u201356 (2013).","journal-title":"Am. J. Kidney Dis."},{"key":"357_CR33","doi-asserted-by":"publisher","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","volume":"359","author":"CE Dunbar","year":"2018","unstructured":"Dunbar, C. E. et al. Gene therapy comes of age. Science 359, eaan4672 (2018).","journal-title":"Science"},{"key":"357_CR34","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1261\/rna.2300406","volume":"12","author":"L Yen","year":"2006","unstructured":"Yen, L., Magnier, M., Weissleder, R., Stockwell, B. R. & Mulligan, R. C. Identification of inhibitors of ribozyme self-cleavage in mammalian cells via high-throughput screening of chemical libraries. RNA 12, 797\u2013806 (2006).","journal-title":"RNA"},{"key":"357_CR35","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1182\/blood.V92.5.1512","volume":"92","author":"D Bohl","year":"1998","unstructured":"Bohl, D., Salvetti, A., Moullier, P. & Heard, J. M. Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector. Blood 92, 1512\u20131517 (1998).","journal-title":"Blood"},{"key":"357_CR36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1056\/NEJMc1606202","volume":"376","author":"S Blum","year":"2017","unstructured":"Blum, S. et al. TARGT gene therapy platform for correction of anemia in end-stage renal disease. N. Engl. J. Med. 376, 189\u2013191 (2017).","journal-title":"N. Engl. J. Med."},{"key":"357_CR37","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.V10112392","volume":"10","author":"IC Macdougall","year":"1999","unstructured":"Macdougall, I. C. et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J. Am. Soc. Nephrol. 10, 2392\u20132395 (1999).","journal-title":"J. Am. Soc. Nephrol."},{"key":"357_CR38","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1182\/blood-2003-11-3845","volume":"103","author":"P Chenuaud","year":"2004","unstructured":"Chenuaud, P. et al. Autoimmune anemia in macaques following erythropoietin gene therapy. Blood 103, 3303\u20133304 (2004).","journal-title":"Blood"},{"key":"357_CR39","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1182\/blood-2003-11-3852","volume":"103","author":"G Gao","year":"2004","unstructured":"Gao, G. et al. Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 103, 3300\u20133302 (2004).","journal-title":"Blood"},{"key":"357_CR40","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1056\/NEJM200202143460711","volume":"346","author":"HF Bunn","year":"2002","unstructured":"Bunn, H. F. Drug-induced autoimmune red-cell aplasia. N. Engl. J. Med. 346, 522\u2013523 (2002).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41587-019-0357-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41587-019-0357-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41587-019-0357-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:14:06Z","timestamp":1684606446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41587-019-0357-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,23]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["357"],"URL":"https:\/\/doi.org\/10.1038\/s41587-019-0357-y","relation":{},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,23]]},"assertion":[{"value":"1 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.Z. and M.F. are cofounders of Emmune Inc., a startup company that designs AAV-based treatments and prophylaxis for HIV-1.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}